High-dose IV vitamin C as alternative cancer treatment

1. What it was

Version followed: high-dose vitamin C (ascorbate), given intravenously and/or orally, offered instead of standard cancer treatment or as the "main therapy" after standard treatment is set aside. This is distinguished throughout from research use as an adjunct inside ethics-approved clinical trials, which is described here only so clinicians can tell the two apart. Nothing in this guide presents vitamin C as a treatment for cancer. [source: NCI PDQ High-Dose Vitamin C, Health Professional Version; RACGP First Do No Harm]

Origins.

Early 1970s, Scotland: surgeon Ewan Cameron and Allan Campbell reported a case series of 50 patients with advanced cancer given ascorbic acid intravenously and/or by mouth; the authors themselves noted that the absence of controls prevented any firm attribution of benefit (Cameron and Campbell, Chemico-Biological Interactions, 1974). [source: NCI PDQ] The hospital is named in secondary accounts as the Vale of Leven Hospital [uncertain: not verified].
1976: Cameron and the double Nobel laureate Linus Pauling reported 100 "terminal" patients given ascorbate who, they said, survived on average roughly 300 days longer than 1,000 matched controls; a re-evaluation of the same data followed in 1978. These patients started ascorbate after conventional therapy had been judged unlikely to work. [source: NCI PDQ]
1979 and 1985: Mayo Clinic randomised, placebo-controlled trials (Creagan et al. and Moertel et al., New England Journal of Medicine) tested high-dose oral vitamin C in advanced cancer and found no difference from placebo in symptoms, performance status or survival. Neither trial used the intravenous route, which supporters later cited as the reason for the negative results. [source: NCI PDQ; Mayo Clinic Staff, High-dose vitamin C: Can it kill cancer cells?]
2004 onward: pharmacokinetic work (Padayatty et al., Annals of Internal Medicine, 2004) showed that intravenous infusion produces far higher blood concentrations than any oral intake, because absorption from the gut is tightly controlled. Laboratory work proposed that such concentrations generate hydrogen peroxide that harms cancer cells in a dish. This revived interest in IV vitamin C. [source: NCI PDQ; Assouline and Miller, CMAJ 2006]
2006: three case reports of patients with advanced cancer given high-dose IV vitamin C were published in CMAJ. The accompanying commentary noted alternative explanations for each outcome (spontaneous remission, prior surgery, radiotherapy), concurrent use of other remedies, and unreported non-responders. Cancer Research UK warned the report was potentially misleading, stating there was "no clinical evidence to show that high dose vitamin C can treat cancer". [source: Assouline and Miller, CMAJ 2006; Cancer Research UK news, 29 March 2006]

Who used it, where. A survey of practitioners attending complementary and alternative medicine conferences in 2006 and 2008 (published 2010) found 172 of 199 respondents had given IV vitamin C to patients, most often for infections, cancer and fatigue. [source: NCI PDQ] It has been offered in private integrative, naturopathic and "wellness" clinics; the RACGP addresses it as a request patients bring to general practice. [source: RACGP] Some alternative practitioners still recommend high oral doses despite the negative trials. [source: Mayo Clinic Staff]

Stated rationale and how it was sold.

Rationale as proponents give it: at very high blood levels ascorbate acts as a pro-oxidant that "selectively" damages cancer cells while sparing healthy ones; it is "natural" and "non-toxic"; it strengthens immunity and quality of life. [source: NCI PDQ (mechanism as studied); Assouline and Miller] [synthesis: the marketing framing]
Sales appeal: the authority of a Nobel laureate, the 1976 survival figures, case reports, and the argument that the Mayo trials "used the wrong route". [source: NCI PDQ; CMAJ commentary] [synthesis: how these were combined in marketing]
The FDA lists phrases such as "Selectively kills cancer cells" and "Attacks cancer cells, leaving healthy cells intact" among the red flags of fraudulent cancer products. [source: FDA, Products Claiming to "Cure" Cancer Are a Cruel Deception]

Status in one line each.

Regulatory: the FDA has not approved high-dose vitamin C as a treatment for cancer. [source: NCI PDQ, health professional and patient versions] The RACGP's advice is that vitamin C infusions should not be given in general practice except within a properly conducted, ethics-approved clinical trial. [source: RACGP]
Evidence: early studies looked promising but had serious design limitations; benefit has not been established. As an adjunct to chemotherapy, small trials are mixed (a 2024 randomised phase II pancreatic cancer trial reported longer survival when added to chemotherapy; a 2024 randomised phase II prostate cancer trial found no benefit when added to docetaxel; a phase III colorectal trial, NCT02969681, is under way). There is no evidence that vitamin C alone cures cancer. [source: NCI PDQ; Mayo Clinic Staff; RACGP]

2. What was actually done

A typical alternative course, as patients experience it. Qualitative only; no amounts, concentrations or schedules are given.

Route in. Usually self-referral after reading online material, a testimonial, a recommendation from friends or a support community, or a practitioner's website; sometimes after an oncologist has said that further treatment is unlikely to help (the situation of Cameron's original patients). [source: NCI PDQ (patient selection in the early series)] [synthesis: other routes]
Assessment and selection. In research settings, patients are screened and excluded for the main risk factors for toxicity: glucose-6-phosphate dehydrogenase (G6PD) deficiency, kidney disease and a history of kidney stones. [source: NCI PDQ] Whether a given private clinic screens is [uncertain: not verified]; the absence of such screening is a red flag (section 4).
Consent and framing. Where offered as an alternative, consent rests on claims of selective toxicity to cancer, low side effects and the 1976 survival data, often contrasted with the toxicity of chemotherapy. [source: FDA red-flag phrases; NCI PDQ history] [synthesis: the contrast with chemotherapy as a sales frame] Pressure can come from cost already paid, from the practitioner's certainty, or from family and online communities [synthesis].
Setting and staff. Outpatient infusion chairs in private clinics run by doctors, naturopaths or other practitioners; who may lawfully place an IV and administer it varies by jurisdiction [uncertain: not verified for each jurisdiction].
Sessions. Repeated intravenous drips over a course of treatment. [source: NCI PDQ] Patients may experience increased urine output, thirst, nausea, vomiting and chills during or after an infusion. [source: NCI PDQ, 2015 trial] Fluid overload was reported in one study, possibly from the volume of fluid used to deliver the infusion. [source: NCI PDQ patient version]
Combined products. In case series of people using IV vitamin C as their "main therapy", it was combined with other vitamins, minerals and botanicals. [source: NCI PDQ] Oral high-dose vitamin C was also used between or instead of infusions (the original Cameron and Pauling approach used both routes). [source: NCI PDQ]
Home component. Oral supplements and dietary advice; further detail is [uncertain: not verified].
Judging "progress". How alternative providers judge progress is [uncertain: not verified]. Clinically important: people who use high-dose vitamin C and check glucose at home or in hospital may get unreliable readings ("glucometer error" is a documented harm). [source: Yanase et al. 2020]
Non-response or refusal. How providers handle non-response or refusal is [uncertain: not verified]. A common pattern to listen for is the course being extended or more products added when the cancer progresses, rather than a return to the oncology team [synthesis].

Named variants.

Cameron-Pauling regime (1970s): IV and oral ascorbate in patients considered beyond conventional treatment. [source: NCI PDQ]
High-dose oral vitamin C: tested and found ineffective in the Mayo trials; still recommended by some alternative practitioners. [source: NCI PDQ; Mayo Clinic Staff]
"Pharmacologic" IV ascorbate as adjunct in trials: legitimate research, with screening, monitoring and standard treatment continued. [source: NCI PDQ]
General "vitamin drips": infusions promoted for sepsis, herpes zoster, COVID-19 and other conditions, for which the RACGP finds no supporting evidence; the TGA issued a safety alert that there is no evidence for IV high-dose vitamin C for COVID-19. [source: RACGP, including its summary of the TGA alert]

3. How it caused harm

1. Delay or abandonment of effective cancer treatment (the main harm). When an alternative replaces surgery, chemotherapy or radiotherapy, survival falls. In a US National Cancer Database study of 840 patients with breast, prostate, lung or colorectal cancer (Johnson et al., Journal of the National Cancer Institute), those who chose alternative medicine instead of conventional treatment had a higher risk of death; the excess risk persisted for breast, lung and colorectal cancer. This study covered alternative medicine generally, not vitamin C specifically. [source: Futurity report of Johnson et al.] At risk: people with curable or controllable cancers, people frightened of chemotherapy, those who distrust medicine, and people persuaded by "selective, non-toxic" claims. [synthesis]

2. Kidney injury. Ascorbate is metabolised to oxalic acid, which can form calcium oxalate crystals, especially when kidney function is already reduced. [source: RACGP] Kidney failure has been reported after treatment in people with a history of kidney disease, and people likely to form kidney stones are advised to avoid it. [source: NCI PDQ patient version] A scoping review of harm from IV high-dose vitamin C in adults found reports of oxalate nephropathy (5 cases) and kidney stones (1 case). [source: Yanase et al. 2020] Kidney damage may be compounded by dehydration from vomiting and by chemotherapy drugs that also affect the kidneys [synthesis].

3. Haemolysis in G6PD deficiency. People with this inherited enzyme deficiency should not receive high-dose vitamin C because it can break down red blood cells (haemolysis); the scoping review found 3 such cases. [source: NCI PDQ patient version; RACGP; Yanase et al. 2020] G6PD deficiency is more common in people of African, Mediterranean, Middle Eastern and Asian ancestry [synthesis: general clinical knowledge, not from the cited sources].

4. Other documented physical harms.

Hypernatraemia (high blood sodium): 5 cases in the scoping review. [source: Yanase et al. 2020]
Glucometer error: 2 cases; unreliable point-of-care glucose readings matter for people with diabetes or on steroids. [source: Yanase et al. 2020] [synthesis: clinical consequence]
Iron overload: high-dose vitamin C may increase iron absorption and is not recommended in haemochromatosis. [source: NCI PDQ patient version; RACGP]
Fluid overload, possibly from the delivery volume. [source: NCI PDQ patient version]
Interference with cancer drugs: in some laboratory and animal studies, combining vitamin C with certain anticancer drugs made them work less well; the RACGP advises it not be given with bortezomib. Cancer Research UK warned in 2006 that high doses may limit the effectiveness of radiotherapy and chemotherapy. [source: NCI PDQ; RACGP; Cancer Research UK 2006]
In double-blind trials that screened out high-risk patients, IV high-dose vitamin C was not consistently more harmful than placebo. The harms above therefore concentrate in unscreened, unmonitored settings and in people with the listed risk factors. [source: Yanase et al. 2020; NCI PDQ] [synthesis: the inference about unscreened settings]

5. Psychological, relational and financial harm [synthesis: the cited sources document survival and physical harms; the following is clinical inference and should be explored, not assumed].

False hope followed by sharper despair when the cancer progresses; regret and self-blame ("I chose this") in patients and bereaved relatives.
Family conflict between relatives who support and oppose the choice, sometimes continuing as blame after death.
Rupture with the oncology team, so the person arrives late and ashamed when symptoms worsen, sometimes missing timely palliative care.
Out-of-pocket costs for repeated private infusions and accompanying products, debt, crowdfunding, and loss of savings intended for family.
Lost time and energy in the last months of life spent travelling to infusions.

Case examples. Individual case reports of oxalate nephropathy, haemolysis and hypernatraemia are summarised in the scoping review by Yanase et al. (2020); individual patients are not named here. [source: Yanase et al. 2020]

Most at risk. People with kidney disease or a history of kidney stones; people with G6PD deficiency; people with haemochromatosis; people on chemotherapy drugs that may interact; people with diabetes relying on glucose meters; people with curable cancers who decline standard treatment; children whose parents choose alternatives on their behalf. [source: NCI PDQ; RACGP; Yanase et al. 2020] [synthesis: children]

4. Recognising it today

Phrases and rationales that signal the alternative framing. [source: FDA red-flag list; NCI PDQ; RACGP] [synthesis: application to vitamin C]

"Selectively kills cancer cells", "attacks cancer, leaves healthy cells alone", "more effective than chemotherapy", "non-toxic", "cures cancer" (all on the FDA red-flag list).
"Pharmacologic ascorbate" or "high-dose vitamin C therapy" offered as a stand-alone or "main" treatment, or as a reason to postpone surgery, chemotherapy or radiotherapy.
Appeals to Linus Pauling's authority or the 1976 survival figures, with the Mayo trials dismissed because they "used the wrong route".
Selected laboratory or early-phase trial results presented as proof of cure; the existence of genuine adjunct research used as if it validated use instead of treatment.
Packages bundling IV vitamin C with other vitamins, minerals, botanicals and diets, sold as an "integrative protocol" by a clinic that does not work with the person's oncologist.
Rebrandings: "vitamin drip", "immune drip", "IV nutrient therapy", "orthomolecular oncology", "metabolic therapy" [synthesis: names as commonly marketed; not from the cited sources].

Red flags in a colleague's or service's practice. [synthesis, informed by RACGP and NCI PDQ]

Offering or administering vitamin C infusions for cancer outside an ethics-approved clinical trial (the RACGP's "do not do").
No screening for G6PD deficiency or kidney disease, no kidney monitoring, and no enquiry about chemotherapy drugs such as bortezomib.
Advising the person not to tell, or to stop seeing, their oncologist; describing standard treatment as poison.
Testimonials as the main evidence; up-front payment for long courses; financial ties to the clinic or products.
A psychotherapist, coach or support group referring clients to infusion providers, selling products, or receiving referral fees (conflict of interest; APA Standard 3.06). [source: APA Ethics Code]

How legitimate use differs. [source: NCI PDQ; RACGP; Mayo Clinic Staff]

Given only as an adjunct alongside standard treatment, inside a registered trial with ethics approval, under the oncology team.
Screening excludes people with G6PD deficiency, kidney disease and kidney stones; side effects are monitored and reported.
The consent form states that benefit is not established and that the FDA has not approved it for cancer.
The person's oncologist knows and agrees.

Where it turns up in a therapy room. [synthesis]

A client mentions "drips" or "vitamin infusions" in passing while describing their cancer care.
A client is "taking a break" from chemotherapy, or has declined surgery, and speaks of a clinic with great hope or secrecy.
Family members bring conflict about a relative's choice; a bereaved relative describes a parent's or partner's months of infusions with guilt or anger.
Financial stress (fundraising, debt) linked to private cancer "treatment".

5. What to do instead and how to help those harmed

Recommended alternatives (the psychotherapist refers and coordinates; never prescribes). [source: NCI PDQ; RACGP; Mayo Clinic Staff]

Standard cancer treatment as recommended by the treating oncology team.
Ethics-approved clinical trials, including trials of IV vitamin C as an adjunct, discussed with the oncologist (the RACGP's only acceptable setting for infusions).
Integrative oncology as its professional societies describe it, complementary to and never instead of standard care (see entry 172).
Early palliative care referral for symptom control and quality of life, alongside or after active treatment [synthesis: referral practice].
Psycho-oncology support for fear, uncertainty, decision conflict and grief.

The psychotherapist's role is psychological: the person's decision is theirs, and medical questions about vitamin C go to the oncologist, GP or pharmacist. The psychotherapist never performs, sells, recommends or advises starting or stopping vitamin C or any treatment. [source: APA Ethics Code 2.01, 3.06, Principle E] [synthesis: application]

5.1 Asking about complementary and alternative use, without judgement

Purpose: find out early whether a client with cancer (or a relative) is using or considering IV vitamin C or other alternatives; make it safe to disclose.
Steps: (1) Ask routinely at intake and at review, for all clients with a cancer diagnosis or caring for someone who has one. (2) Normalise: many people try something outside standard care. (3) Ask what, from whom, how often in broad terms, cost, and whether the oncologist knows. (4) Record it factually in the notes. [synthesis; RACGP's "explore their health beliefs" applied]
Example language (illustrative): "Lots of people having cancer treatment also try things like vitamins, drips or diets. Is anything like that part of your plan at the moment, or something you're weighing up?"
Watch for: guarded answers, sudden topic changes, phrases from section 4, or a client who has stopped mentioning the oncology team. Working: the client volunteers details at later sessions.

5.2 Exploring meaning, hopes and expectations

Purpose: understand what draws the person to vitamin C: hope, control, fear of chemotherapy side effects, distrust after a bad experience, identity ("natural" person), a community, or a loved one's wish.
Steps: (1) Ask what the person expects the infusions to do, as the RACGP advises GPs to do. (2) Reflect the values beneath (wanting to be active, to avoid suffering, to stay alive for children). (3) Explore the explanatory model: what they believe caused the cancer and what will heal it. (4) Hold back from correcting facts at this stage. [source: RACGP] [synthesis: steps 2 to 4]
Example language (illustrative): "What are you hoping the vitamin C will do for you?" / "It sounds like having something you can choose for yourself matters a lot right now."
Watch for: expectations of cure (higher risk) versus hopes of feeling better while continuing treatment (lower risk); intense fear of chemotherapy that may be treatable in its own right (needle or medical-procedure fear, past trauma). Working: the person can name their values and fears separately from the product.

5.3 Autonomy-respecting decision support

Purpose: help the person make an informed, values-based decision without coercion, recognising that adults with capacity may decline treatment.
Steps: (1) Ask permission before sharing information. (2) Encourage the person to put specific questions to the oncologist: what happens if standard treatment is delayed, what the realistic outcomes are with and without it, whether vitamin C would interact with their drugs, whether a trial is available. (3) Share, if invited, that the FDA has not approved high-dose vitamin C for cancer, that benefit has not been established, and that the RACGP advises it only within trials. (4) Use a decisional-balance or values-clarification conversation [synthesis; no specific published decision aid is endorsed here]. (5) Separate "adding something" from "replacing treatment". (6) Respect the decision; keep the door open. [source: NCI PDQ; RACGP; APA Ethics Code Principle E] [synthesis: process]
Example language (illustrative): "Would it help to write down the questions you want to ask your oncologist about this before your next appointment?" / "Some people use vitamin C alongside their treatment in research studies, and some use it instead. Those are quite different choices. Which one are you thinking about?"
Watch for: your own urge to persuade or rescue (rupture risk); the client feeling judged; capacity concerns (delirium, brain metastases, severe depression) that need medical assessment. Working: the person feels heard, has spoken with the oncologist, and the decision fits their stated values.

5.4 Coordination with the treating doctor, oncology and palliative teams

Purpose: make sure the medical team knows about infusions so that kidney function, G6PD status, drug interactions and glucose readings can be checked.
Steps: (1) Seek the client's consent to contact the GP or oncologist; explain why (safety, not policing). (2) Share only what is necessary. (3) Encourage the client to tell the team themselves where possible. (4) If the person is moving away from active treatment, raise palliative care referral with the team. [source: APA Ethics Code 3.09, 4.05; NCI PDQ; RACGP] [synthesis: steps]
Example language (illustrative): "Infusions can affect the kidneys and some cancer drugs, so your doctors would want to know. Would you be OK with me letting them know, or would you rather tell them yourself?"
Watch for: refusal of consent (respect it unless a legal duty applies; keep discussing); the oncology relationship having broken down (help repair it, or support a second opinion). Working: the team is informed and the client stays connected to medical care.

5.5 Recognising and responding to physical risk signals

Purpose: notice when a client may be experiencing a medical complication and route them to urgent care; the psychotherapist does not diagnose.
Steps: (1) Know the documented risks: kidney injury, haemolysis in G6PD deficiency, high sodium, fluid overload, misleading glucose readings, drug interactions. (2) If a client reports reduced urine, severe vomiting, dark urine, unusual tiredness, breathlessness or swelling after infusions, advise prompt medical review. (3) Document. [source: NCI PDQ; RACGP; Yanase et al. 2020] [synthesis: symptom prompts]
Example language (illustrative): "That sounds like something a doctor should look at today. Can we work out together who you'll call?"
Watch for: minimisation ("it's just detox"); in many alternative framings, worsening symptoms are described as the treatment working [uncertain: not verified for vitamin C providers]. Working: the client seeks medical review promptly.

5.6 Assessment of clients who went through an alternative course

Purpose: understand the psychological sequelae for a patient who has returned to standard care, or a relative after a death. [synthesis throughout]
Steps: (1) Take a narrative of the decision and its context without evaluating it. (2) Screen for depression, anxiety, suicidal thinking (standard risk assessment), complicated or prolonged grief, and trauma symptoms linked to diagnosis or treatment. (3) Assess shame and self-blame, anger at the provider, and trust in current clinicians. (4) Ask about money and debt. (5) Check current medical connection.
Example language (illustrative): "Looking back on those months, what do you find yourself thinking about most?"
Watch for: hindsight bias ("I should have known"), shame that blocks medical follow-up, and suicidal thinking in people facing progressive disease. Working: the story can be told with less shame, and the person re-engages with care.

5.7 Grief and regret

Purpose: help patients and bereaved relatives with regret, guilt and anger after choosing, supporting or failing to stop an alternative course. [synthesis throughout]
Steps: (1) Validate that the choice was made with the information, fear and hope available at the time. (2) Distinguish responsibility from blame; explore the role of persuasive marketing (section 4) without removing the person's agency. (3) Use established grief approaches for prolonged grief where indicated. (4) Address anger at the provider, including whether to report (5.10). (5) For patients still living, work on what matters in the time ahead, with palliative care input.
Example language (illustrative): "You made the best decision you could with what you were told and what you were afraid of. Can we look at what you knew then, rather than what you know now?"
Watch for: rumination fixed on the decision; one relative carrying all the blame; delayed grief in someone who led the choice. Working: self-compassion statements, less rumination, re-engagement with life roles.

5.8 Family conflict

Purpose: reduce conflict between relatives who support and oppose the choice, and support the patient's relationships. [synthesis throughout]
Steps: (1) With the patient's consent, meet the family or advise the client on conversations. (2) Name the shared aim (everyone wants the patient to live and suffer less). (3) Help relatives express worry without ultimatums. (4) Respect the patient's decision as an adult with capacity. (5) After a death, address blame between relatives.
Example language (illustrative): "It sounds like everyone in this room is frightened of losing her, and that fear is coming out in different ways."
Watch for: coercion in either direction (pressure to use or to refuse alternatives); a relative or practitioner controlling access to information. Working: conversations stay respectful and the patient feels less torn.

5.9 Financial harm

Purpose: identify and respond to financial strain or exploitation. [synthesis throughout]
Steps: (1) Ask about costs, debt, crowdfunding and pressure to prepay. (2) Signpost to financial counselling, hospital social work or consumer advice. (3) Explore whether consumer or advertising complaints are wanted (5.10).
Example language (illustrative): "Has paying for the infusions put pressure on you or the family?"
Watch for: prepaid packages, escalating costs when the cancer progresses, and relatives selling assets. Working: the person has a plan and support for the financial side.

5.10 Safeguarding and reporting

Purpose: meet ethical and legal duties without breaching confidentiality unnecessarily.
Steps:
1. Children: if a parent declines effective cancer treatment for a child in favour of an alternative, or a child is given infusions outside medical care, consult the child's treating team and follow local child-protection procedures; involve the child's assent according to age and understanding. [synthesis; safeguarding guidance [uncertain: not verified]; follow your jurisdiction's procedures]
2. Adults at risk: consider adult-safeguarding procedures where an adult lacks capacity or is being coerced or financially exploited. [synthesis]
3. Confidentiality: disclose without consent only where law requires it or a recognised purpose such as preventing harm applies, and share no more than necessary (APA Standard 4.05). [source: APA Ethics Code]
4. Product and marketing complaints (US): the FDA takes reports of product problems (1-888-INFO-FDA, or its "Report a Product Problem" option). [source: FDA consumer update] Advertising and consumer regulators (such as the FTC in the US) and, elsewhere, the national medicines regulator (such as the TGA in Australia) are the usual routes [uncertain: not verified].
5. Practitioners: complaints about a licensed practitioner go to the relevant licensing board (medical, nursing, naturopathic where regulated) [uncertain: not verified for each jurisdiction].
6. Document decisions and consultations. [synthesis]
Example language (illustrative): "If you decide you want to make a complaint about the clinic, I can help you think through where it would go. That's your choice."
Watch for: the client's fear of reprisal or shame; your own anger leading you to act beyond the client's wishes where no duty applies. Working: duties met, client informed, therapeutic relationship intact.

5.11 Managing the therapist's own stance and conflicts

Purpose: keep the work within competence and free of conflicts. [source: APA Ethics Code 2.01, 3.04, 3.05, 3.06, 10.01] [synthesis: application]
Steps: (1) Stay within psychological scope; route medical questions to clinicians. (2) Never refer to, sell or profit from infusion providers or products. (3) Seek supervision when your own views (strongly for or against) are shaping sessions. (4) Explain your role and its limits in the informed-consent conversation.
Example language (illustrative): "My part is helping you think this through and cope with it; the medical side is one for your oncologist."
Watch for: persuading, lecturing, or quietly withdrawing warmth when a client chooses differently from your view. Working: the client keeps talking openly about their choices.

5.12 Handling common difficulties

[synthesis throughout]

Client will not discuss it: respect the boundary; return to values and wellbeing; keep the invitation open.
Client asks your opinion: give a brief, honest, non-coercive answer pointing to the oncologist and the regulator's position; then return to their values.
Strong distrust of doctors: explore the history behind it (past dismissal, trauma, discrimination); support a second opinion rather than an alternative.
Rupture after you raised safety: acknowledge it, own your part, restate respect for their autonomy.
Client in a supportive online or group community promoting it: explore belonging and identity needs; watch for high-control dynamics such as discouraging contact with doctors or family.

Sources

Papers cited via the NCI PDQ summary:

Cameron E, Campbell A. Chemico-Biological Interactions, 1974.
Cameron E, Pauling L. 1976, and the 1978 re-evaluation [uncertain: full citations not verified].
Creagan ET et al. New England Journal of Medicine, 1979.
Moertel CG et al. New England Journal of Medicine, 1985.
Padayatty SJ et al. Annals of Internal Medicine, 2004.
Johnson SB et al. Journal of the National Cancer Institute (reported 2017; issue year 2018) [uncertain: full citation not verified].

← Previous · XII-160Insulin potentiation therapy Next · XII-162 →714-X (Naessens)